Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD – The Liver Meeting®

December 15, 2023

https://www.globenewswire.com/news-release/2023/11/09/2777768/14025/en/Arbutus-Biopharma-and-Barinthus-Bio-Present-Preliminary-Data-from-Phase-2a-Clinical-Trial-Combining-Imdusiran-with-VTP-300-at-AASLD-The-Liver-Meeting.html

The combination of imdusiran and VTP-300 provides a meaningful reduction of HBsAg levels that are maintained well below baseline

Preliminary data in subset of patients given imdusiran and then VTP-300 show early signs of immune activation

Read more at globenewswire.com

Related news for (ABUS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.